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ABSTRACT
microRNAs play an important roles in cell growth,
differentiation, proliferation and apoptosis. They can
function either as tumor suppressors or oncogenes.
We found that the overexpression of miR-192 in-
hibited cell proliferation in A549, H460 and 95D
cells, and inhibited tumorigenesis in a nude mouse
model. Both caspase-7 and the PARP protein
were activated by the overexpression of miR-192,
thus suggesting that miR-192 induces cell apoptosis
through the caspase pathway. Further studies
showed that retinoblastoma 1 (RB1) is a direct
target of miR-192. Over-expression of miR-192
decreased RB1 mRNA and protein levels and re-
pressed RB1-30-UTR reporter activity. Knockdown
of RB1 using siRNA resulted in a similar cell morph-
ology as that observed for overexpression of
miR-192. Additionally, RB1-siRNA treatment in-
hibited cell proliferation and induced cell apoptosis
in lung cancer cells. Analysis of miRNA expression
in clinical samples showed that miR-192 is signifi-
cantly downregulated in lung cancer tissues
compared to adjacent non-cancerous lung tissues.
In conclusion, our results demonstrate that miR-192
is a tumor suppressor that can target the RB1 gene
to inhibit cell proliferation and induce cell apoptosis
in lung cancer cells. Furthermore, miR-192 was ex-
pressed at low levels in lung cancer samples,
indicating that it might be a promising therapeutic
target for lung cancer treatment.
INTRODUCTION
microRNAs (miRNAs) are single-stranded non-coding
small RNAs of  22 nt that can regulate gene expression
in animals, plants and viruses (1). miRNAs are ﬁrst
transcribed by RNA polymerase II as primary miRNAs
(pri-miRNAs) that are several thousand nucleotides long
(2,3). Pri-miRNAs are processed by the microprocessor
complex, which is composed of the RNase III type
enzyme, Drosha and the double-stranded RNA binding
protein, DiGeorge syndrome critical region gene 8
(DGCR8), to generate  70 nt precursor miRNAs
(pre-miRNAs) with hairpin-shaped structures (4,5).
These pre-miRNAs are exported to the cytoplasm by
exportin-5 (Exp-5) and the cofactor Ran-GTP (6). In the
cytoplasm, pre-miRNAs are processed into 22 nt mature
miRNA duplexes by the RNase III Dicer enzyme (7).
Mature miRNAs are incorporated into ‘miRNA-
containing RNA-induced silencing complex (miRISC),
which induce either cleavage or translational repression
of targeted mRNAs (1,8). The miRNA database
(miRBase16.0) contains 1048 records, and the number of
known miRNAs is still growing (http://microrna.sanger
.ac.uk) (9).
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entiation, proliferation, apoptosis and cell death. miRNAs
associated with tumorigenesis act as either tumor suppres-
sors or oncogenes. For example, let-7 in lung cancer (10)
and the miR15a/16 cluster in CLL act as tumor suppres-
sors (11). In contrast, the miR-17-92 cluster in malignant
lymphoma (12) and miR-155/BIC in Burkitt lymphoma
(13) act as oncogenes.
miR-192 was ﬁrst cloned by Lagos-Quintana et al. (14)
and later conﬁrmed by Lim et al. (15). The miR-192 gene
is located on human chromosome 11 and is transcribed as
a cluster with miR-194 (16). miR-192 sequence mutations
have been identiﬁed in some hepatocellular carcinoma
(HCC) tissues, but may not represent the primary mech-
anism of hepatocarcinogenesis (17). The expression of
miR-192 can be regulated by hepatocyte nuclear
factor-1a (HNF-1a) (16), transforming growth factor
b (TGF-b) and p53 (18,19). In the kidney, miR-192
controls TGF-b-induced Col1a2 expression by
downregulating the E-box repressor survival of motor
neuron protein interacting protein 1 (SIP1) (20), and
miR-192 targets WNK1 in regulation of sodium and po-
tassium balance (21). In breast cancer, both miR-192 and
bone morphogenetic protein-6 can inhibit delaEF1 expres-
sion to prevent breast cancer cell migration (22). In colon
cancer, miR-192 targets transcriptional thymidylate
synthase (TYMS) to inﬂuence 5-ﬂuorouracil resistance
(23) and targets DHFR to regulate cellular proliferation
through the p53-microRNA circuit (24). Additional
studies have shown that p53 induces miR-192 expression
and down-regulates the genes that regulate G1 and G2
checkpoints, resulting in cell cycle arrest in G1 or G2
(18,25).
RB1 was the ﬁrst described tumor suppressor. It can
stabilize the constitutive heterochromatin to maintain
the overall chromatin structure. It can bind the transcrip-
tion factor E2F1 and regulate the expression of many
genes. One of the functions of RB1 is to inhibit apoptosis
(26,27). Knockdown of RB-induced apoptosis can be
canceled by overexpression of miR-17–92 in lung cancer
cells (28). Lung cancer is the leading cause of death
throughout the world. miRNA might play the important
roles in lung cancers (29,30).
In the current study, we found that miR-192 is
downregulated in lung cancer tissue compared with re-
spective non-cancerous lung tissue. Overexpression of
miR-192 inhibits cell proliferation and promotes cell
apoptosis in lung cancer cells, and miR-192 inhibits
tumorigenesis in a nude mouse model in vivo. Further
analysis showed that RB1 is an important target of
miR-192 in lung cancer cells.
MATERIALS AND METHODS
Cell culture and tissue sample collection
A549, NCI-H460 (H460 cell) and 95D cells (all of them
were human lung cancer cell lines) were maintained in
Ham’s F12 (F12) or RPMI-1640 (1640) medium; HeLa
(cervical cancer cell line) and HEK293 (Human
Embryonic Kidney 293 cell line) cells were maintained in
Dulbecco’s Modiﬁed Eagle’s medium (DMEM). All
media were supplemented with 10% fetal bovine serum
(FBS, Hyclone, USA) and 1% antibiotics (100U/ml peni-
cillin and 100mg/ml streptomycin sulfate). Cells were
grown in an atmosphere of 5% CO2 at 37 C. All cell
lines were a kind gift from Dr Duanqing Pei’s Lab at
the Guangzhou Institute of Biomedicine and Health,
Guangzhu, China 510530.
The A549-luc-2 cell line was constructed in our lab by
transfecting the pGL4 vector (Promega, USA) into A549
cells and selecting cell lines with stable expression of the
luciferase protein. The cell line was maintained in 1640
medium supplemented with 10% FBS and 800 U/ml of
G418 antibiotic.
Seventeen lung cancer tissues and respective non-cancer
lung tissues were obtained from the Guangzhou Institute
of Respiratory Disease, the First Afﬁliated Hospital of
Guangzhou Medical College (Guangzhou, China) in
2008 with informed consent and Institutional Review
Board (IRB) permission. All clinical and biological data
were available for the samples. Samples were separated
from the surgical patient samples and immediately
snap-frozen in liquid nitrogen and stored in liquid
nitrogen until use.
Synthesis and transfection of siRNAs, miRNA mimics
and miRNA inhibitors
siRNAs, miRNA mimics and miRNA inhibitors were
designed and synthesized by Guangzhou RiboBio
(RiboBio, China). miRNA inhibitors were all nucleotides
with 20-O-methyl modiﬁcation. Three siRNAs targeting
on RB1 gene were designed and synthesised, the most
effective siRNA (siRB1) identiﬁed by qPCR was applied
for the further experiments. The sequence of siRB1 is:
sense: 50-CACCCAGGCGAGGUCAGAAdTdT-30;
anti-sense: 30-dTdTGUGGGUCCGCUCCAGUCUU-50.
Twenty-four hours prior to transfection, cells were plated
onto a 96-well plate (Greiner, Germany) at  40–60% con-
ﬂuence. Transfection was performed with Lipofectamine
2000 (Invitrogen, USA) according to the manufacturer’s
protocol. The medium was replaced 4–6h after transfec-
tion with new culture medium, except in the case of
HEK293 cells, for which the medium was not replaced
after transfection.
Apoptosis assay
A549, HeLa, and HEK293 cells were transfected with
50nM of the miRNA mimics. Forty-eight hours after
transfection, 20ml of MTT (5mg/ml) was added to each
well of a 96-well plate and the cells were cultured for 4h.
The MTT medium mixture was then discarded and 150ml
of dimethyl sulfoxide (DMSO) was added to each well.
Absorbance was measured at 570nm using a multi-well
spectrophotometer (Bio-Tek, USA).
Cell viability was measured using the Celltiter-Glo
luminescent cell viability assay kit (Promega, USA)
according to the manufacturer’s protocol. Brieﬂy, A549,
HEK293, HeLa, H460 and 95D cells were plated onto
96-well plates. Forty-eight hours after transfection, the
6670 Nucleic Acids Research, 2011,Vol.39, No. 15Celltiter-Glo reagent was added and luminescent intensity
was read by a Microplate Luminometer (Turner
Biosystems, USA) using the respective Promega protocols.
Cell apoptosis was also detected using an Annexin V-PE
apoptosis detection kit (BD, USA) according to the manu-
facturer’s protocol and FACS analysis (BD, USA).
5-ethynyl-20-deoxyuridine assay
A549 and H460 cells were transfected with miRNA
mimics in 96-well plates. Forty-eight hours after transfec-
tion, 5-ethynyl-20-deoxyuridine (EdU) (100mM) (Cell
Light EdU DNA imaging Kit, Guangzhou RiboBio,
China) was added and the cells were cultured for an add-
itional 2h. The cells were then stained according to the
following protocol: discard the EdU medium mixture, add
4% paraformaldehyde to ﬁx cells at room temperature for
30min, wash with glycine (2mg/ml) for 5min in a shaker,
add 0.2% Trion X-100 for 10min, wash with PBS for two
times, add click reaction buffer (Tris–HCl, pH 8.5,
100mM; CuSO4, 1mM; Apollo 550 ﬂuorescent azide,
100mM; ascorbic acid, 100mM) for 10–30min while pro-
tecting from light, wash with 0.5% Triton X-100 for three
times, stain with Hoechst (5mg/ml) for 30min at room
temperature, wash with 0.5% Triton X-100 for ﬁve
times, and, ﬁnally, add 150ml PBS. Images were taken
and analyzed using High Content Imaging Pathway 855
(BD, USA). EdU positive cell was caculated with (EdU
add-in cells/Hoechst stained cells) 100%.
Cell cycle assay
A549 cells were transfected with miR-192 or no-target
control, 24h later, Nocodazole (40ng/ml) was added.
Cells were collected after 48h and stained with propidium
iodide (PI) for cell cycle analysis with FACS (BD, USA).
Data were collected and analyzed with the CELLQuest
and ModFit LT software.
RNA extraction and qRT–PCR
Total RNA was extracted from cell lines and tissue
samples using Trizol reagent (Invitrogen, USA) according
to the manufacturer’s protocol. cDNA was synthesized
from 2mg of total RNA with M-MLV Reverse
Transcriptase (Promega, USA) in a 25ml volume {2mg
total RNA, 400mM reverse transcription primer
[oligo(dT)18 for mRNA genes, random primers for U6
rRNA and miRNA speciﬁc primers (Bulge-Loop
TM
miRNA qPCR Primers from RiboBio, China) for
miRNA], 4U/ml M-MLV, 1U/ml inhibitor, 0.4mM
dNTP mix}. Real time PCR was carried out with the
reagents of a Sybr green I mix (Takara, China) in a
20ml reaction volume (10ml Sybr green I mix, 200mM
forward and reverse primer, 2ml cDNA template) on a
MJ Opticon Monitor chromo4 instrument (Bio-Rad,
USA) using the following protocol: 95 C for 20s; 40
cycles of 95 C for 10s, 60 C for 20s, 70 C for 1s. Data
analysis were performed using the 2
 Ct method (31).
Western blot
Cells were washed with PBS chilled to 4 C. Whole-cell
proteins were extracted with cell lysis buffer (Beyotime,
China) that included the protease inhibitor phenylmetha-
nesulfonyl ﬂuoride (PMSF, Beyotime, China) at 4 C for
half an hour and separated by 15% sulfate–polyacryl-
amide gel electrophoresis (SDS–PAGE). The proteins
and the pre-stained marker (Fermantas, USA) were then
transferred onto an Immobilon-P transfer polyvinylidene
ﬂuoride membrane (PDVF, pore size: 0.45mm; Millipore,
USA) with a Semi-dry Transfer Cell (Model 755, Bio-Rad,
USA) for 90min, allowing the pre-stained marker to be
completely transferred from the gel to the membrane. The
gel was discarded and the membrane was incubated at
room temperature in 5% non-fat milk prepared with
TBS-T buffer. Two hours later, the membrane was cut
as required (as b-Actin is  37kDa; RB1, 130kDa;
cleaved caspase7, 20kDa; PARP, 116 and 89 kDa),
placed in a suitable hybridization bag with 1ml of
primary antibody [all primary antibodies were diluted
1:1000 with 1% non-fat milk; the anti-b-Actin antibody
was obtained from Sigma, USA; the anti-RB1(H4)
antibody, the PARP antibody, and the cleaved caspase7
antibody were all obtained from Cell Signal Technology,
USA] and incubated at 4 C overnight. The membrane was
washed three times with TBS-T and the secondary
antibody was added [goat anti-rabbit antibody for
Actin, cleaved caspase7 and PARP; goat anti-mouse
antibody for RB1; both of the secondary antibodies
were conjugated to horseradish peroxidase (HRP) and
were obtained from Santa Cruz, USA] for 2h at room
temperature. The membrane was washed three times
with TBS-T buffer and incubated with HRP substrate
(BeyoECL plus A/B, Beyotime, China) for 1min. Blots
were developed on X-ﬁlm (Kodak, Japan).
Luciferase reporter assay
The 30-UTRs of the predicted target genes were PCR
ampliﬁed from genomic DNA of A549 cells, which was
extracted with a Genomic DNA Extraction kit (Dingguo,
China). The PCR products were gel puriﬁed, digested and
inserted into the digested psicheck-2 plasmid (Promega,
USA) between the XhoI and NotI sites. RB1-30-UTR
target site mutations were introduced using the
KOD-plus mutagenesis kit (Toyobo, Japan) according to
the manufacturer’s protocol. All inserted or mutated se-
quences were conﬁrmed by sequencing. All primers were
synthesized by Guangzhou RiboBio (RiboBio, China),
and the sequences of the primers are available upon
request.
Two hundred nanogram per microliter of plasmid and
50nM miRNA mimics were co-transfected into A549
cells. Forty-eight hours after transfection, luciferase
activity was detected using the Dual-Glo luciferase assay
kit (Promega, USA) according to the manufacturer’s
protocol. Luminescence intensity was read with a
Microplate Luminometer using the respective Promega
protocol. Transfections were performed in duplicate and
repeated three times.
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All experimental procedures involving animals were per-
formed according to the institutional ethical guidelines for
animal experiments at the Guangzhou Institute of
Medicine and Health, Chinese Academy of Sciences.
A549-luc-2 cells were pre-treated with 50nM of miR-192
mimics or a non-targeting control, mock control were also
included. After 6h transfection, new medium was added
to the cells. Twelve hours after transfection, cells were
collected and suspended in 100ml PBS at a concentration
of 1 10
6 cells/ml and injected s.c. into either side of the
posterior ﬂank of the same BALB/c athymic nude mouse
(5–6 weeks of age, each group with at least four mouse,
n=4) (32). Thirty minutes after cell injection, luciferase
substrate was added at a dose of 150mg/kg and live
images of the mouse were obtained using an IVIS200
(Xenogene, USA). These data were classiﬁed as Day 0.
Luciferase activity was measured every 4 days using the
same protocol. Tumor growth was examined every 2 days
beginning at Day 4. Tumor volume (V) was monitored by
measuring the length (L) and width (W) with calipers and
calculated with the formula V=(L W
2) 0.5.
Statistical analysis
Data are presented as means±(SEM) from at least three
separate experiments. Multiple group comparisons were
performed with ANOVA (P<0.05).
RESULTS
miR-192 inhibits cell proliferation in A549 cells
Several miRNAs, including miR-21, 24, 106a, 150 and
192, have been found to be differentially expressed in
lung cancers, but the role of these miRNAs in lung car-
cinogenesis and tumor growth requires clariﬁcation (6).
We performed a cell viability assay demonstrating that
the relative cell viability was dramatically decreased by
48.4% (P<0.05) when cells were treated with miR-192
(Figure 1A). However, no obvious changes in the
growth of HEK293 or Hela cells were observed after treat-
ment with miR-192 or the miRNA mimics (Figure 1A). In
addition, we examined the cell viability of A549 cells
treated with different doses of miR-192 and miR-191 (a
randomly selected control). As shown in Figure 1B,
miR-192 suppressed A549 cell viability in a
dose-dependent manner. At doses of 1, 10 and 50nM,
treatment with miR-192 signiﬁcantly (P<0.05) lowered
cell viability by 23.4, 32.5 and 57.2%, respectively,
compared with the same concentrations of non-targeting
control (Notarget) miRNA. A549 cells are deﬁcient of
Mre11A gene, which encodes a nuclear protein involved
in homologous recombination, telomere length mainten-
ance and DNA double-strand break repair. But siRNA
knockdown of Mre11A did not make Hela cells or
HEK293 cells sensitive to miR-192 reduced cell viability
(Supplementary Figure S1), so deletion of Mre11a may
not be the result of miR-192 reduced cell viability in
A549 cells.
miR-192 induces cell apoptosis in A549 cells
Previous reports have shown that expression of miR-192
can arrest cells in G1 phase and reduce S phase entry in
colon cancer cells (18,25). We conducted an EdU cell pro-
liferation assay to determine whether miR-192 suppresses
the entry of A549 cells into S phase. A comparison of
treatments with miR-192 and with the notarget control
miRNA (Figure 2A) indicated that the proportion of
cells incorporating EdU was decreased by 42.9±5.3%
(P<0.05). Moreover, we examined cell apoptosis in
A549 cells using an AnnexinV-PE apoptosis detection
kit and found that levels of cell apoptosis were elevated
by  5-fold in cells exposed to miR-192 versus the
Notarget control (Figure 2B). Further experiments
revealed that miR-192 induced the expression of poly
(ADP-ribose) polymerase (PARP) and of cleaved
Caspase-7 (Figure 2C), members of a well-known apop-
tosis pathway. Cell cycle assay results showed that
miR-192 arrested cell in G1 phase, at 18.63±1.96%
compared with 7.33±0.52 of Notarget control
(Figure 2D). Taken together, our data indicates that
Figure 1. miR-192 inhibits cell viability. (A) Cell viability of A549,
HEK293 and HeLa by Celltiter assay. Cells were transfected with
50nM of miRNA mimics or non-targeting control (Notarget) in
96-well plate. Cell viability assays were performed 48h after transfec-
tion, Celltiter-Glo reagent was added and luminescent intensity was
measured by a Microplate Luminometer. (B) Cell viability with differ-
ent concentrations of miRNA mimics. A549 cells were transfected with
50, 10 and 1nM miRNA mimics and Notarget control in 96-well plate.
Cell viability assays were performed 48h after transfection. Relative
luminescence was calculated with luminescencemiRNA/luminescence
Notarget. Data were the average of three independent experiment runs;
bars, SEM. *P<0.05; **P<0.01, compared with Notarget control.
6672 Nucleic Acids Research, 2011,Vol.39, No. 15miR-192 suppresses A549 cell growth via inhibition of
proliferation and enhancement of apoptosis.
RB1 is a target of miR-192 in A549 cell
We used three open access programs—picTar, TargetScan
and miRnaDa—to predict targets of miR-192. Four cell
cycle-related genes (CDK7, RB1, CCNE1, RAB2A) that
were potential miR-192 targets were selected for further
analysis. The 30-UTRs of these four genes were cloned into
the psiCheck-2 plasmid (the predicted binding sites for
miR-192 are shown in Figure 3A). The luciferase
reporter assay indicated that the activity of the reporter
containing the 30-UTR of the RB1 gene was decreased
following treatment with miR-192 mimics, whereas the
reporters containing the 30-UTRs of the other genes
were not obviously altered (Figure 3A). We performed
site-directed mutagenesis of the reporter containing the
30-UTR of the RB1 gene as described in Figure 3B and
the luciferase reporter assay was performed with the
mutated construct. The results demonstrate that the in-
hibitory effect of miR-192 mimics was abolished in the
mutant reporter (Figure 3B). In addition, real time PCR
and western blot analysis revealed that the expression of
RB1 mRNA and protein was impaired by the treatment
with miR-192 mimics in A549 cells (Figure 3C and D). We
have also examined whether RB1 reverse the inhibition of
cell viability and cell proliferation caused by miR-192
overexpression in the lung cancer cells. The vector of
pRB that contains only the RB1-coding sequence was
Figure 2. Cell apoptosis induced by miR-192. (A) EdU assay of relative Hoechst stained cells and EdU add-in cells. A549 cells were transfected with
50nM miRNA mimics, miRNA inhibitor (ant-miR192, fully 20 O-methyl modiﬁed RNA oligo) or Notarget control. Forty-eight hours after trans-
fection, EdU (100mM) was added and the cells were cultured for 2h. EdU and Hoechst staining were performed as described in ‘Materials and
Methods’ section. At least 200 cells were counted per well. (B) miR-192 induces A549 cell apoptosis. A549 cells were transfected with 50nM miR-192
mimics, ani-miR192 or Notarget control, 48h after transfection, apoptosis assay was performed. (C) Western blot analysis of b-Actin, cleaved PARP
and Caspase7 after 48h of treatment with miR-192 or Notarget control. (D) Cell cycle of miR-192 and Notarget-treated A549 cells. Nocodazole
(40ng/ml) were added after 24h transfection, cells were collected after 48h and stained with PI and cell cycle was analyzed with FACS. Data were
the averages of at least three independent runs; bars, SEM. *P<0.05; compared with Notarget control.
Nucleic Acids Research, 2011,Vol.39, No. 15 6673constructed for RB1 expression without miR-192 target-
ing. The cells were co-transfected with miR-192 mimics
and either pRB or pNEG empty vector. The assays
clearly showed that ectopic expression of RB1 signiﬁcantly
rescued the suppression of cell viability and cell prolifer-
ation caused by miR-192 overexpression (Supplementary
Data, Supplementary Figures S2 and S3). Taken together,
our results demonstrated that RB1 is a major target of
miR-192 in the lung cancer cells.
RNAi knockdown of RB1 inhibits cell proliferation and
induces cell apoptosis in lung cancer cells
The efﬁciency of siRB1 in the knockdown of RB1 expres-
sion was examined by western blot and qPCR (Figure 4B
and C). The siRB1 was then used in cell viability,
apoptosis and EdU detection assays. The results shown
in Figure 4A demonstrated that treatment with RB1
siRNA resulted in a statistically signiﬁcant inhibition of
viability of A549, H460 and 95D cells. Caspase-7 activa-
tion was also observed following treatment with siRB1 in
these three cell lines (Figure 4B). EdU assay in A549 and
H460 cells show that the cell number is signiﬁcantly
reduced in RB1 siRNA-treated cells compared with
notarget control. These experiments provided further
evidence that RB1 is one of the direct targets of
miR-192 in lung cancer cells.
Expressions of miR-192 is downregulated in human lung
cancers
Expression of miR-192 has been reported to be suppressed
in colon cancers (18). We compared the endogenous
Figure 3. RB1 is one of the direct targets of miR-192. (A) The binding site of miR-192 in the predicted target sequences. A549 cells were
co-transfected with 50nM of miR-192 mimics or Notarget control and 200ng/ml of 30-UTR reporter plasmid. Luciferase activity was detected at
48h after transfection. (B) miR-192 binding site in the 30-UTR of the RB1 mRNA. A mutation was generated in the RB1-30-UTR sequence in the
complementary site for the seed region of miR-192 as indicated. A549 cells were co-transfected with 50nM miR-192 mimics or Notarget controls and
200ng/ml of RB1 30-UTR reporter plasmid or its mutant form. Luciferase activity was detected 48h after transfection. (C) Total RNA was extracted
and real time PCR was performed 48h after transfection. (D) miR-192 inhibits RB1 protein expression in A549 cells. Total protein was extracted and
western blot analysis was performed 48h after transfection. Relative luciferase activity was calculated with (RlucmiRNA/LucmiRNA)/(RlucNotarget/
LucNotarget). Data represented the average of three independent runs; bars, SEM. *P<0.05; **P<0.01, compared with Notarget control.
6674 Nucleic Acids Research, 2011,Vol.39, No. 15expression of miR-192 in human lung cancer and adjacent
non-cancerous lung tissues by qRT–PCR. As shown in
Figure 5, expression of miR-192 was downregulated by
up to 50% (P<0.001) in 71% (12 out of 17) of lung
cancer tissues compared with the corresponding adjacent
non-cancerous lung tissues. One lung cancer sample dis-
played a 2-fold upregulation of miR-192 expression. These
results indicate that miR-192 may act as a tumor suppres-
sor gene.
miR-192 inhibits tumorigenicity in vivo
To conﬁrm the tumor suppressor role of miR-192, we es-
tablished a BALB/c nude mouse xenograft model using a
stable cell line derived from human lung cancer A549 cells
(A549-luc). The A549-luc cells were pre-treated with
miR-192 or a Notarget control and injected s.c. into
either posterior ﬂank of the same nude mouse. The
luciferase activity and tumor volume were measured
every 4 days until Day 20. The ﬂuorescence intensity of
A549-luc cells treated with Notarget control miRNA
decreased at Day 4 and dramatically increased thereafter
until Day 20, whereas the intensity of A549 cells treated
with miR-192 mimics increased slowly after Day 4
(Figure 6A and B). The tumor volume in the ﬂanks
injected with miR-192 mimic pre-treated cells was also
signiﬁcantly (P<0.05) smaller than the volume in the
ﬂanks injected with Notarget control pre-treated cells at
every indicated time point from Day 4 on (Figure 6C).
These results indicate that miR-192 signiﬁcantly inhibits
tumorigenicity of A549 cells in vivo in a nude mouse xeno-
graft model.
Figure 4. siRB1 inhibits cell proliferation and induces cell apoptosis (A) Cell viability of A549, H460, 95D cells. Cell viability assays were performed
with 50nM siRB1, miR-192 mimics or Notarget control, 48h after transfection, Celltiter-Glo reagent was added and luminescent intensity was read
by a Microplate Luminometer. (B) Western blot analysis of RB1, cleavge Caspase 7 after treatment with miR-192 mimics, siRB1 and notarget
control (NC). (C) RB1 mRNA expression in A549, H460 and 95D cells after transfected with 50nM miR-192 mimics, siRB1 and Notarget control
for 48h, b-Actin was used as an internal control. (D) EdU assay of Hoechst stained cells and EdU add-in cells. Cells were transfected with miR-192
mimics, siRB1 and Notarget control at 50nM. EdU assay were performed 48h after transfection. Data were the averages of three independent runs;
bars, SEM. *P<0.05, compared with Notarget control.
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Our results clearly show that miR-192 inhibits cell prolif-
eration of A549, H460 and 95D lung cancer cells and
induces cell apoptosis. In colon cancer cells, miR-192
inhibits the cell proliferation depending on the status
of p53; the inhibition efﬁciency is higher in cells
with wild-type p53 than in cells with null or mutant
p53 (24,25). A549, H460, 95D, HEK293 and HeLa cells
all express wild-type p53, but miR-192 expression had no
effect on HeLa or HEK293 cell proliferation. These results
indicate that the p53 protein may play a partial role in
determining which cell lines may be affected by expression
of miR-192, but that there are likely other factors involved
in the mechanism of miR-192 action (25). Our EdU assay
showed that both the total number of cells and the number
of cells with newly synthesized DNA dramatically
decreased after treatment with miR-192 mimics. EdU
was added just 2h before detection, indicating that at
least during this 2-h period the number of DNA
synthesizing cells (reﬂecting cells in S-phase of the cell
cycle) was lower in the miR-192-treated samples than in
the Notarget-treated controls. This result is similar to that
observed in colon cancer cells, in which miR-192 prevents
cells from completing the G1-S transition and delays cell
cycle progression (18).
miR-192 inhibits cell proliferation and induces cell
apoptosis in A549, H460 and 95D cells. The rate of apop-
tosis of miR-192 mimic-treated A549 cells was more than
4-fold greater than the rate in Notarget or mock
control-treated cells. Both PARP and/or Caspase 7 were
cleaved in A549, H460 or 95D cells after treatment with
miR-192 mimics. These ﬁndings indicate that miR-192
induces lung cancer cell apoptosis through the caspase
pathway.
Figure 6. miR-192 inhibits tumorigenicity in vivo in BALB/c nude mice. (A) Images of one miR-192-treated mice after 20 days implantation.
Fluorescence intensity (B) and tumor volume (C) of miR-192 mimics, Notarget control, and mock control-treated mice were measured at the
indicated days after treatment (each group with four mouse, n=4; data are reperest means±SEM; *P<0.05).
Figure 5. miR-192 expression in 17 lung cancer tissues. Stem loop RT–
PCR analysis of miR-192 in lung cancer tissues and adjacent
non-cancerous lung tissues. U6 rRNA was used as an internal
control. 2
 Ct method was used to analyze the qPCR data. The pos-
itions of 2-fold overexpression or 2-fold downexpression were drawn a
dashed line, respectively.
6676 Nucleic Acids Research, 2011,Vol.39, No. 15RB1 was the ﬁrst cancer suppressor gene to be
identiﬁed. It not only plays important roles in childhood
retinoblastoma (RB), bladder cancer and osteogenic
sarcoma, but also plays a vital role in regulating cell apop-
tosis. Knockdown of the Rb gene has been shown to
induce g-H2AX foci formation, a marker of DNA
damage, and to promote cellular apoptosis in A549 cells
(28). Overexpression of the p16 gene induces cleavage of
RB and ultimately induces apoptosis in A549 cells (33). In
RB-deleted CC42 (Rb
 / ), myocytes (CC42 cells were
isolated from Rb null mutation mouse stem cells)
undergo higher frequencies of apoptosis during mitogen
deprivation-induced myogenesis, while overexpression of
RB inhibited apoptosis in Rb deleted or wide-type CC42
cells (27). RB can also protect Saos-2 cells from E2F1
overexpression iduced cell apoptosis, but cannot protect
E2F1 mutant (1–376 or 406–415 site mutant)
overexpression induced cell apoptosis (26). We found
that miR-192 regulates RB1 expression at both the
mRNA and the protein levels (Figure 4B and C);
miR-192 expression and siRB1 knockdown of the RB1
gene both inhibited A549, H460 and 95D cell proliferation
and induced cell apoptosis. Additionally, expression of
miR-192 repressed RB1 30-UTR reporter activity.
Overexpression of RB1 without 30-UTR can signiﬁcantly
reverse the inhibition of miR-192. These results conﬁrm
that RB1 is one of the direct targets of miR-192 in lung
cancer cells.
Some miR-192 targets have been identiﬁed in different
cells and organs. miR-192 plays a role in the kidney and
diabetic nephropathy by regulating SIP1 (20), and it also
targets dihydrofolate reductase (DHFR) in colon cancer
to control the cell cycle (24). Microarray experiments have
shown that 62 genes are downregulated following
miR-192 expression, 8 of which have been validated as
targets of miR-192 involved in cell cycle control (18).
miR-192 may be a critical downstream mediator of
TGF-b/Smad3 signaling in the development of renal
ﬁbrosis, but the exact targets involved in this process are
unknown (19). The miR-192/194 cluster plays a role in the
circadian clock at the post-transcriptional level, but again
the targets involved are unknown (34). We found RB1 to
be a novel target of miR-192 involved in cell apoptosis.
Additional targets remain to be identiﬁed.
Our results demonstrate that miR-192 is downregulated
in lung cancer tissues compared to adjacent non-tumor
lung tissue. miR-192 is also downregulated in the lungs
of rats exposed to cigarette smoke (35), and repressed in
colon cancer (36), ulcerative colitis (37), multiple myeloma
(38), diabetic nephropathy (39), while miR-192
upregulated in lgA nephropathy (40,41) and in hyperten-
sive nephrosclerosis (42). Furthermore, miR-192 can be
downregulated by genotoxic stress in colon cancer cells
(18,25). Ectopic overexpression of miR-192 inhibits cell
proliferation in vitro and tumorigenicity in vivo in a nude
mouse model. These results suggest that miR-192 is a
tumor suppressor and indicate that it may be useful as a
future drug target for controlling cancer progression.
In summary, our results demonstrate the following:
miR-192 is downregulated in human lung cancer tissues
compared to adjacent non-cancerous lung tissues;
miR-192 mimics inhibit cell proliferation and induce cell
apoptosis in lung cancer cells and inhibit tumorigenicity in
a nude mouse model in vivo; and RB1 is likely a bona ﬁde
target of miR-192. Our data suggest that miR-192 is an
important tumor suppressor that could be exploited in
lung cancer therapy.
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